International Consolidated Airlines Group SA
Change company Symbol lookup
Select an option...
ICAGY International Consolidated Airlines Group SA
$NQUSS451020JPYT Nasdaq US Small Cap Food Producers T
LULU Lululemon Athletica Inc
AICAF Air China Ltd
OBMP OncBioMune Pharmaceuticals Inc
AVNW Aviat Networks Inc
AMPY Amplify Energy Corp
JEPI JPMorgan Equity Premium Income ETF
ABBV Abbvie Inc
VOLAF Volvo AB
Go

Industrials : Airlines | Large Cap Value
Based in United Kingdom
Company profile

International Consolidated Airlines Group, S.A. is an airline company that holds the interests in airline and ancillary operations. Its segments include British Airways, Iberia, Vueling, Aer Lingus and Other Group companies. It combines the airlines in the United Kingdom, Spain and Ireland. It has approximately 573 aircrafts to over 268 destinations. The Company operates various aircraft fleet services, including Airbus A318, Airbus A319, Airbus A340-600, Boeing 787-800, Embraer E190 and Boeing 777-200, among others. The Company, through its subsidiaries, is engaged in providing airline marketing, airline operations, insurance, aircraft maintenance, storage and custody services, air freight operations and cargo transport services. The Company offers its services in cities, including London, Madrid, Barcelona, Rome and Dublin. The Company's brands include British Airways, Iberia, LEVEL, Vueling, Aer Lingus, IAG Cargo and Avios.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$5.80
Day's Change
0.0401 (0.70%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.84
Day's Low
5.76
Volume
(Light)
Volume:
265,347

10-day average volume:
340,747
265,347

Odonate Therapeutics stock plummets toward record low after plan to 'wind down' operations

1:36 pm ET March 22, 2021 (MarketWatch)
Print

Shares of Odonate Therapeutics Inc. (ODT) plummeted 79.0% in active afternoon trading Monday, after the pharmaceutical company said it will wind down operations following disappointing data from its cancer treatment. The company said it determined, following feedback from the Food and Drug Administration in a pre-New Drug Application (pre-NDA) meeting, that tesetaxel, an orally administered chemotherapy agent, is unlikely to receive FDA approval. "Therefore, the company is discontinuing the development of tesetaxel and will wind down the operations of the company," the company said in a statement. Since going public in December 2017 at an initial public offering price of $24, the stock has traded in a closing price range of $11.78 (Dec. 27, 2018) to $45.63 (June 16, 2020); on Friday, the stock closed at $19.03. The stock has lost 73.9% over the past three months, while the S&P 500 has gained 7.0%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

	

(END) Dow Jones Newswires

March 22, 2021 13:36 ET (17:36 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.